Allogeneic CD19 CAR-T Cells for the Treatment of Relapsed/Refractory B-cell Lymphoma

Clinical trial NCT05143112 · UNKNOWN

Trial details

NCT number: NCT05143112
Sponsor: Shenzhen University General Hospital
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Non-hodgkin Lymphoma,B Cell

Start date: 2021-02-05
Primary completion: 2024-02-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.